The serum prostate-specific antigen(PSA) test has been used for the detectionof PCa at early stages and is also routinely utilizedto monitor PCa recurrence after therapy.However, this has limited accuracy in predictingtreatment outcomes and making clinical decisions(3) necessitating urgently the need for additional prognostic markers for PCa. Here, KLK3 is linked to posterior cortical atrophy.